Top

Published in:

Open Access 01-02-2010 | Topic Paper

Role of voiding and storage symptoms for the quality of life before and after treatment in men with voiding dysfunction

Authors: Petros Sountoulides, Marleen M. van Dijk, Hessel Wijkstra, Jean J. M. C. H. de la Rosette, Martin Christian Michel

Published in: World Journal of Urology | Issue 1/2010

Abstract

Purpose

Previous studies on associations between voiding dysfunction and quality of life (QoL) have largely been limited to baseline data. Therefore, we have explored associations between Q _max and voiding and storage sub-scores of the International Prostate Symptom Score (IPSS) before and after treatment with QoL.

Methods

Analysis of a single-center database of 2,316 men with voiding dysfunction attributed to benign prostatic hyperplasia undergoing various medical and surgical treatment forms.

Results

Q_max exhibited little correlation with QoL before or after treatment. IPSS inversely correlated with QoL at baseline and after treatment, and IPSS improvements correlated with those of QoL. The associations applied to both the voiding and storage sub-score of the IPSS, with the latter consistently exhibiting somewhat tighter associations.

Conclusions

Our post-treatment data support the idea of a cause–effect relationship between voiding symptoms and QoL irrespective of treatment form. While both voiding and storage symptoms contribute to this relationship, storage symptoms play a somewhat greater role.

Welch G, Kawachi I, Barry MJ et al (1998) Distinction between symptoms of voiding and filling in benign prostatic hyperplasia: findings from the health professionals follow-up study. Urology 51:422–427CrossRefPubMed

Kaplan SA, Roehrborn CG, Chapple CR et al (2009) Implications of recent epidemiology studies for the clinical management of lower urinary tract symptoms. BJU Int 103(Suppl 3):48–57CrossRefPubMed

Donovan JL (2000) The measurement of symptoms, quality of life and sexual function. BJU Int 85(Suppl 1):10–19CrossRefPubMed

Engström G, Henningsohn L, Walker-Engström M-L et al (2006) Impact on quality of life of different lower urinary tract symptoms in men measured by the Short Form 36 SF 36 questionnaire. Scand J Urol Nephrol 40:485–494CrossRefPubMed

Tubaro A, La Vecchia C (2004) The relation of lower urinary tract symptoms with life-style factors and objective measures of benign prostatic enlargement and obstruction: an Italian survey. Eur Urol 45:767–772CrossRefPubMed

Robertson C, Link CL, Onel E et al (2007) The impact of lower urinary tract symptoms and comorbidities on quality of life: the BACH and UREPIK studies. BJU Int 99:347–354CrossRefPubMed

Peters TJ, Donovan JL, Kay HE et al (1997) The International Continence Society “benign prostatic hyperplasia” study: the bothersomeness of urinary symptoms. J Urol 157:885–889CrossRefPubMed

Yoshimura K, Arai Y, Ichioka K et al (2002) Symptom-specific quality of life in patients with benign prostatic hyperplasia. Int J Urol 9:485–490CrossRefPubMed

Coyne KS, Wein AJ, Tubaro A et al (2009) The burden of lower urinary tract symptoms: evaluating the effects of LUTS on health-related quality of life, anxiety and depression: EpiLUTS. BJU Int 103(Suppl 3):4–11CrossRefPubMed

10.

Sexton CC, Coyne KS, Kopp ZS et al (2009) The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: EpiLUTS. BJU Int 103(Suppl 3):12–23CrossRefPubMed

11.

Salinas-Sanchez AS, Hernandez-Millan I, Lorenzo-Romero JG et al (2001) Quality of life of patients on the waiting list for benign prostatic hyperplasia surgery. Quality Life Res 10:543–553CrossRef

12.

Araki I, Tsuchida T, Nomura T et al (2008) Differential impact of lower urinary tract symptoms on generic and disease-specific quality of life in men and women. Urol Int 81:60–65CrossRefPubMed

13.

Marklund-Bau H, Edell-Gustafsson U, Spangberg A (2007) Bothersome urinary symptoms and disease-specific quality of life in patients with benign prostatic obstruction. Scand J Urol Nephrol 41:32–41CrossRefPubMed

14.

Batista-Miranda JE, De la Cruz Diez M, Arano Betran P et al (2001) Quality-of-life assessment in patients with benign prostatic hyperplasia. Effects of various interventions. Pharmacoeconomics 19:1079–1090CrossRefPubMed

15.

Lepor H, Auerbach S, Puras-Baez A et al (1992) A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol 148:1467–1474PubMed

16.

Fabricius PG, Hannaford JM (1992) Placebo-controlled study of terazosin in the treatment of benign prostatic hyperplasia with 2-year follow up. Urology 70(Suppl 1):10–16

17.

Chapple CR, Wyndaele JJ, Nordling J et al (1996) Tamsulosin, the first prostate-selective α_1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol 29:155–167PubMed

18.

Lee E, Lee C (1997) Clinical comparison of selective and non-selective α₁A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses. Br J Urol 80:606–611PubMed

19.

Lepor H (1998) Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Urology 51:892–900CrossRefPubMed

20.

Kirby RS, Andersen M, Gratzke P et al (2001) A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia. BJU Int 87:192–200CrossRefPubMed

21.

Michel MC, Flannery MT, Narayan P (2001) Worldwide experience with alfuzosin and tamsulosin. Urology 58:508–516CrossRefPubMed

22.

Roehrborn C, van Kerrebroeck P, Nordling J (2003) Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int 92:257–261CrossRefPubMed

23.

Djavan B, Milani S, Davies J et al (2005) The impact of tamsulosin oral controlled absorption system (OCAS) on nocturia and the quality of sleep: preliminary results of a pilot study. Eur Urol Suppl 4:61–68CrossRef

24.

Wasson JH, Reda DJ, Bruskewitz RC et al (1995) A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. New Engl J Med 332:75–79CrossRefPubMed

25.

Yalla SV, Sullivan MP, Lecamwasam HS et al (1995) Correlation of American Urological Association symptom index with obstructive and nonobstructive prostatism. J Urol 153:674–680CrossRefPubMed

26.

NRjr Netto, D’Ancona CAL, de Lima ML (1996) Correlation between the International Prostatic Symptom Score and a pressure-flow study in the evaluation of symptomatic benign prostatic hyperplasia. J Urol 155:200–202CrossRef

27.

Lee K-S, Lee HW, Han DH (2008) Does anticholinergic medication have a role in treating men with overactive bladder and benign prostatic hyperplasia? Naunyn-Schmiedeberg’s Arch Pharmacol 377:491–501CrossRef

Title: Role of voiding and storage symptoms for the quality of life before and after treatment in men with voiding dysfunction
Authors: Petros Sountoulides
Marleen M. van Dijk
Hessel Wijkstra
Jean J. M. C. H. de la Rosette
Martin Christian Michel
Publication date: 01-02-2010
Publisher: Springer-Verlag
Published in: World Journal of Urology / Issue 1/2010
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-009-0480-3

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Role of voiding and storage symptoms for the quality of life before and after treatment in men with voiding dysfunction

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2010

Urinary collecting system invasion reflects adverse long-term outcome and is associated with simultaneous metastatic spread at the time of surgery and with multilocular dissemination during postsurgical follow-up in renal cell cancer

Complications of laser prostatectomy: a review of recent data

Relevance of benign prostatic hyperplasia and associated conditions for urologists, health care systems, and society

Factors predicting inguinal node metastasis in squamous cell cancer of penis

Thulium laser enucleation of the prostate (ThuLEP): transurethral anatomical prostatectomy with laser support. Introduction of a novel technique for the treatment of benign prostatic obstruction

Triple therapy in refractory detrusor overactivity: a preliminary study